Get the Stockscreener App
2.26
0.89%
0.02
Alpha Tau Medical Ltd stock is traded at $2.26, with a volume of 1,038.
It is up +0.89% in the last 24 hours and down -0.88% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
See More
Previous Close:
$2.24
Open:
$2.27
24h Volume:
1,038
Relative Volume:
0.05
Market Cap:
$156.63M
Revenue:
-
Net Income/Loss:
$-28.95M
P/E Ratio:
-7.0625
EPS:
-0.32
Net Cash Flow:
$-29.35M
1W Performance:
-3.00%
1M Performance:
-0.88%
6M Performance:
-9.24%
1Y Performance:
-29.38%
1-Day Range:
$2.217
$2.27
1-Week Range:
$2.20
$2.34
52-Week Range:
$1.75
$3.40
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) Receives $19.20 Average Target Price from Analysts - Defense World
Spire Global, Inc. (NYSE:SPIR) Receives $13.67 Average Target Price from Brokerages - Defense World
Brokerages Set Silvaco Group, Inc. (NASDAQ:SVCO) PT at $20.83 - Defense World
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $34.60 - Defense World
Orthofix Medical (NASDAQ:OFIX) and Alpha Tau Medical (NASDAQ:DRTS) Financial Contrast - Defense World
Comparing Alpha Tau Medical (NASDAQ:DRTS) and Beyond Air (NASDAQ:XAIR) - Defense World
Discover Alpha Tau Medical And 2 Other US Penny Stocks - Simply Wall St
Head-To-Head Review: Biotricity (NASDAQ:BTCY) vs. Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Joins FDA Program to Advance Cancer Therapy - TipRanks
Alpha Tau Announces Acceptance Into FDA’s Total Product - GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - Yahoo Finance
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Reaffirmed by HC Wainwright - Defense World
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright - Investing.com
Alpha Emitter Market Size to witness nearly $1751.5 Million By 2032 - 대구포스트
Alpha Tau treats first lung cancer patient with radiation therapy in Jerusalem - Mugglehead
Alpha Tau Treats First Patient with Recurrent Lung Cancer - ForexTV.com
Alpha Tau Medical Ltd. Treats First Patient with Recurrent Lung Cancer - Marketscreener.com
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Marketscreener.com
Radiopharmaceutical Market 2024 – Industry Opportunities, Challenges, Value Chain and Sales Channels Analysis 2032 | Clarity Pharmaceuticals - 대구포스트
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Expands By 23.9% - MarketBeat
Alpha Emitter Market Outlook, Key Trends and Growth Projections from 2024 to 2032 - 대구포스트
Alpha Emitter Market on the Rise: A Study on its Growth Prospects - openPR
Point72 DIFC Ltd Acquires Shares of 18,774 ChampionX Co. (NASDAQ:CHX) - Defense World
Alpha Tau Medical Ltd.FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC - Marketscreener.com
FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment - Yahoo Finance
Global Alpha Emitter Market Set to Reach $ 1751.5 Million by 2032, Expanding at 11.25% CAGR - 대구포스트
Alpha Tau’s Alpha DaRT Gains FDA Study Approval - TipRanks
Alpha Tau Medical Ltd. Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC - Marketscreener.com
Alpha Tau Announces FDA Approval of IDE to Initiate - GlobeNewswire
Sidoti Events, LLC's Virtual September Small-Cap Conference - Yahoo Finance
Alpha Tau Medical Share PriceDRTS, RNS News, Articles, Quotes, & Charts (NASDAQ:DRTS) - Proactive Investors Australia
Alpha Tau Medical’s Alpha DaRT Technology Shows Breakthrough Results in Cancer Trials - Proactive Investors Australia
23,323 Shares in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Purchased by Caprock Group LLC - Defense World
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 5.3% - Defense World
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Up 63.4% in August - MarketBeat
Top 230+ startups in Radiation Therapy Devices in Sep, 2024 - Tracxn
Radiotherapy Devices Market Scope In The New Analysis By Leading Research Firm - WhaTech
Kromek Group (LON:KMK) Share Price Passes Below 200-Day Moving Average of $6.56 - Defense World
Aptus Capital Advisors LLC Raises Holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS) - Defense World
Aptus Capital Advisors LLC Sells 1,326 Shares of JPMorgan Municipal ETF (BATS:JMUB) - Defense World
Medical Lasers Market 2024: Exploring Industry Demand, Technological Advancements, And Future Prospects - WhaTech
Oncology Devices Market Key Trends, Latest Insights, Future Trends And Forecast To 2033 - WhaTech
DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT - Yahoo Finance
Financial Comparison: Assure (NASDAQ:IONM) versus Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HP Inc. (NYSE:HPQ) Shares Sold by Cambridge Investment Research Advisors Inc. - Defense World
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):